Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability
The impact of health insurance with inequitable rituximab coverage on the survival of patients with diffuse large B-cell lymphoma (DLBCL) has never been reported. We conducted a nationwide multicenter analysis on the outcome of 553 adult patients consecutively diagnosed with DLBCL between July 2003...
Saved in:
Main Authors: | Tanin Intragumtornchai, Udomsak Bunworasate, Noppadol Siritanaratkul, Archrob Khuhapinant, Weerasak Nawarawong, Lalita Norasetthada, Arnuparp Lekhakula, Pairaya Rujirojindakul, Chittima Sirijerachai, Kanjana Chansung, Tawatchai Suwanban, Suporn Chuncharunee, Pimjai Niparuck, Somchai Wongkhantee, Wichean Mongkonsritragoon, Tontanai Numbenjapon |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84870893023&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/52304 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability
by: Tanin Intragumtornchai, et al.
Published: (2018) -
Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability
by: Tanin Intragumtornchai, et al.
Published: (2018) -
Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry
by: Kitsada Wudhikarn, et al.
Published: (2018) -
Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry
by: Kitsada Wudhikarn, et al.
Published: (2018) -
Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma
by: Kitsada Wudhikarn, et al.
Published: (2020)